GO:0034382 chylomicron remnant clearance: Hepatic Lipid Clearance Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034382 chylomicron remnant clearance is the biological process by which chylomicron remnants are removed from the blood via receptor-mediated endocytosis into liver cells and degraded.
• The process is the final, rate-limiting step of dietary fat and vitamin transport, determining how quickly postprandial lipids are cleared from circulation.
• Impaired clearance is documented in familial combined hyperlipidemia, heterozygous familial hypercholesterolaemia, and hypertriglyceridemia.
• Kinetic studies using retinyl esters and vitamin A loading provide direct measures of chylomicron remnant clearance in humans.
• Dietary composition, including fat quantity and type, can modulate chylomicron and chylomicron remnant clearance.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect the hepatic receptor and apolipoprotein machinery controlling this process.
Description
Chylomicron remnant clearance (GO:0034382) is the biological process in which chylomicron remnants are removed from the blood via receptor-mediated endocytosis into liver cells and their constituent parts degraded. This process represents the terminal step of exogenous lipid transport, converting large triglyceride-rich chylomicrons into smaller remnants that are rapidly taken up by the liver. Because it determines the residence time of atherogenic remnant particles in circulation, chylomicron remnant clearance is a central determinant of postprandial lipemia and cardiovascular risk. Researchers study this process to understand how dietary fat, apolipoproteins, and hepatic receptors interact to maintain lipid homeostasis. Defects in clearance are linked to common dyslipidemias, including familial combined hyperlipidemia and heterozygous familial hypercholesterolaemia, making it a target for both mechanistic and translational investigation. Kinetic methods such as vitamin A loading and retinyl ester assays have been used for decades to quantify clearance in healthy and hypertriglyceridemic subjects.
chylomicron remnant clearance At A Glance
| GO ID | GO:0034382 |
|---|---|
| GO term | chylomicron remnant clearance |
| Ontology | biological_process |
| Synonym | none |
| Major function | Receptor-mediated endocytosis of chylomicron remnants into liver cells and degradation of their constituent parts |
| Physiological role | Terminal step of dietary fat and vitamin transport; determines postprandial lipid clearance |
| Tissue context | Primarily liver; involves hepatic receptors and apolipoprotein E |
| Clinical relevance | Impaired in familial combined hyperlipidemia, heterozygous familial hypercholesterolaemia, and hypertriglyceridemia |
| Experimental readouts | Retinyl ester kinetics, vitamin A loading, and postprandial triglyceride measurements |
What Is GO:0034382?
In our own words, GO:0034382 describes the physiological removal of chylomicron remnants from the bloodstream. After a meal, chylomicrons are secreted by the intestine and undergo lipolysis, leaving remnant particles that are enriched in cholesteryl esters and apolipoprotein E. These remnants are then recognized by receptors on liver cells, internalized by receptor-mediated endocytosis, and degraded within the hepatocyte. The QuickGO definition emphasizes that this is a receptor-mediated uptake process occurring in liver cells, followed by degradation of the remnant components.
Why Is chylomicron remnant clearance Important in Cell Biology?
Chylomicron remnant clearance is important because it controls how long atherogenic remnant particles remain in the circulation after a meal. Delayed clearance leads to accumulation of remnants that are enriched in cholesterol and apolipoprotein E, which are associated with increased cardiovascular risk. The process is also the final common pathway for delivery of dietary fats and fat-soluble vitamins to the liver, linking nutrition to systemic lipid metabolism. Clinically, impaired chylomicron remnant clearance has been documented in patients with familial combined hyperlipidemia and heterozygous familial hypercholesterolaemia, providing a mechanistic basis for postprandial dyslipidemia in these conditions. Therefore, understanding the molecular and cellular determinants of this process is essential for developing therapies that target remnant cholesterol and reduce cardiovascular events.
• Determines the residence time of atherogenic chylomicron remnants in blood.
• Controls delivery of dietary fats and fat-soluble vitamins to the liver.
• Impaired in familial combined hyperlipidemia, a common dyslipidemia.
• Delayed in heterozygous familial hypercholesterolaemia.
• Contributes to hypertriglyceridemia pathophysiology.
• Modulated by dietary interventions, including fat quantity and composition.
• Measurable in humans using vitamin A loading and retinyl ester kinetics.
• Provides a target for CRISPR-based functional studies of hepatic receptors and apolipoproteins.
• Relevant to postprandial lipemia and cardiovascular risk assessment.
• Kinetic parameters from normal and hyperlipoproteinemic subjects inform disease mechanisms.
What Happens During chylomicron remnant clearance?
Formation of chylomicron remnants from chylomicrons
In simple terms: After a meal, large fat-carrying particles called chylomicrons lose most of their triglycerides and become smaller remnants.
Chylomicrons are secreted by the intestine and undergo lipolysis in the circulation, which removes core triglycerides and generates smaller, cholesterol-enriched remnant particles. These remnants retain apolipoprotein E and other surface components that are necessary for hepatic recognition. The conversion of chylomicrons to remnants is a prerequisite for their clearance by the liver.
Hepatic recognition and receptor-mediated endocytosis
In simple terms: The liver recognizes remnants through specific receptors and pulls them inside liver cells.
Chylomicron remnants are removed from the blood via receptor-mediated endocytosis into liver cells. This process requires interaction between remnant surface apolipoproteins, particularly apolipoprotein E, and hepatic receptors. The QuickGO definition explicitly states that clearance occurs via receptor-mediated endocytosis into liver cells.
Intracellular degradation of remnant components
In simple terms: Once inside the liver cell, the remnant particle is broken down and its parts are degraded.
After internalization, the constituent parts of the chylomicron remnant are degraded within the liver cell. This degradation step completes the clearance process and releases lipids and other components for hepatic metabolism. The definition of GO:0034382 includes degradation of remnant constituents as part of the process.
Kinetic measurement of clearance in vivo
In simple terms: Doctors and researchers can measure how fast remnants disappear from blood using vitamin A or retinyl esters.
Vitamin A loading has been used as an indicator of postprandial lipoprotein clearance in healthy and hypertriglyceridemic subjects. Kinetic studies of chylomicron remnant clearance have been performed in normal and hyperlipoproteinemic subjects using retinyl ester labels. These methods quantify the rate at which remnants are removed from circulation and have revealed delayed clearance in dyslipidemic states.
Dietary modulation of clearance
In simple terms: What you eat can change how quickly remnants are cleared from your blood.
Dietary interventions affect chylomicron and chylomicron remnant clearance. Studies have shown that the amount and type of dietary fat can influence postprandial clearance rates. This dietary sensitivity makes clearance a modifiable physiological parameter relevant to cardiovascular prevention.
Key Genes Involved in GO:0034382 chylomicron remnant clearance
The genes and proteins below are experimentally implicated in chylomicron remnant clearance, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOE | Surface apolipoprotein on remnants that mediates hepatic receptor recognition | Central ligand for receptor-mediated uptake; knockout and knock-in models used to study clearance |
| LDLR | Hepatic receptor family member implicated in remnant uptake | Target for functional studies of receptor-mediated endocytosis |
| LRP1 | Hepatic receptor involved in chylomicron remnant clearance | Candidate for CRISPR knockout to assess remnant uptake |
| APOB | Structural apolipoprotein of chylomicrons and remnants | Relevant to remnant formation and clearance kinetics |
| APOC3 | Modulates triglyceride-rich lipoprotein metabolism | Linked to hypertriglyceridemia and delayed remnant clearance |
| LPL | Lipoprotein lipase generates remnants from chylomicrons | Determines remnant formation rate and subsequent clearance |
| APOA5 | Regulates triglyceride-rich lipoprotein clearance | Genetic variants associated with hypertriglyceridemia |
| GPIHBP1 | Endothelial protein that facilitates lipolysis of triglyceride-rich lipoproteins | Relevant to remnant generation and postprandial clearance |
| LMF1 | Lipase maturation factor involved in lipase activity | Supports remnant formation for clearance studies |
| CREB3L3 | Transcription factor regulating lipid metabolism genes | Potential regulator of hepatic clearance pathways |
| ANGPTL3 | Inhibitor of lipoprotein lipase and endothelial lipase | Modulates remnant generation and clearance |
| ANGPTL4 | Regulator of lipoprotein lipase activity | Affects postprandial remnant clearance |
| APOC2 | Cofactor for lipoprotein lipase | Required for efficient remnant formation |
| SORT1 | Sortilin, implicated in hepatic lipoprotein uptake | Candidate for receptor-mediated clearance studies |
| VLDLR | Receptor for remnant lipoproteins | Potential alternative clearance receptor |
| ABCA1 | Lipid efflux transporter affecting lipoprotein metabolism | Indirectly influences remnant clearance |
| SCARB1 | Scavenger receptor class B member 1 | Relevant to hepatic lipid uptake |
How Is chylomicron remnant clearance Regulated?
Chylomicron remnant clearance is regulated at multiple levels. Dietary composition, particularly fat intake, modulates the rate of clearance. Apolipoprotein E is a key determinant of hepatic recognition, and its availability or isoforms influence uptake efficiency. Lipoprotein lipase activity, which generates remnants from chylomicrons, is a prerequisite for subsequent clearance. In disease states such as familial combined hyperlipidemia and heterozygous familial hypercholesterolaemia, clearance is delayed, indicating that genetic and metabolic factors regulate this process. Hormonal and nutritional status may also affect clearance, as suggested by vitamin A loading studies in hypertriglyceridemic subjects.
chylomicron remnant clearance and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOE | Familial dysbetalipoproteinemia; impaired remnant clearance | Apoe knockout mouse; CRISPR knock-in of human APOE isoforms |
| LDLR | Heterozygous familial hypercholesterolaemia with delayed remnant clearance | Ldlr knockout mouse; point-mutation knock-in |
| APOC3 | Hypertriglyceridemia | Apoc3 transgenic or knockout models |
| LPL | Hypertriglyceridemia; defective remnant formation | Lpl knockout or point-mutation models |
| APOA5 | Hypertriglyceridemia | Apoa5 knockout mouse |
Familial combined hyperlipidemia
Impaired chylomicron remnant clearance has been demonstrated in patients with familial combined hyperlipidemia. This defect contributes to postprandial lipemia and elevated remnant cholesterol, which are associated with increased cardiovascular risk. The clearance defect is a defining physiological feature of this common dyslipidemia.
Heterozygous familial hypercholesterolaemia
Subjects with heterozygous familial hypercholesterolaemia show delayed chylomicron remnant clearance. This finding links LDL receptor pathway defects to impaired remnant removal, expanding the metabolic consequences of familial hypercholesterolaemia beyond LDL cholesterol. Kinetic studies have confirmed the delay in these patients.
Hypertriglyceridemia
Hypertriglyceridemia is associated with altered chylomicron remnant clearance. The pathophysiology of hypertriglyceridemia involves defects in triglyceride-rich lipoprotein metabolism, including delayed remnant clearance. Vitamin A loading studies have shown abnormal postprandial lipoprotein clearance in hypertriglyceridemic subjects.
Cardiovascular risk
Delayed chylomicron remnant clearance leads to prolonged circulation of atherogenic remnant particles. These remnants are enriched in cholesterol and are thought to contribute to atherosclerosis. Therefore, clearance efficiency is a determinant of cardiovascular risk.
From chylomicron remnant clearance-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate receptor impair chylomicron remnant clearance? | CRISPR knockout in hepatocyte cell lines or mouse liver |
| Does a specific point mutation in APOE alter receptor binding? | CRISPR point-mutation knock-in in cell models |
| Can a human disease-associated variant reproduce delayed clearance? | Knock-in mouse expressing the variant |
| Where does the receptor localize during remnant uptake? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of a candidate gene accelerate clearance? | CRISPR overexpression or transgenic model |
| Which genes regulate postprandial lipid clearance? | CRISPR library screening in hepatocyte models |
How to Study the chylomicron remnant clearance Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Vitamin A loading | Postprandial lipoprotein clearance | Human clinical studies of remnant clearance |
| Retinyl ester kinetics | Chylomicron remnant clearance rate | Comparison of normal and hyperlipoproteinemic subjects |
| Postprandial triglyceride curve | Delayed clearance of triglyceride-rich lipoproteins | Dietary intervention studies |
| CRISPR knockout | Loss-of-function effect on clearance | Testing candidate hepatic receptors |
| CRISPR knock-in | Effect of specific variants on clearance | Modeling human dyslipidemia mutations |
| Overexpression | Gain-of-function effect on clearance | Testing whether a gene accelerates remnant uptake |
| CRISPR library screening | Identification of novel regulators | High-throughput discovery of clearance genes |
Vitamin A loading and retinyl ester kinetics
Vitamin A loading is an established method to assess postprandial lipoprotein clearance in humans. Retinyl esters serve as markers for chylomicron remnants, and their disappearance from plasma reflects clearance rate. These methods have been applied in healthy, hypertriglyceridemic, and hyperlipoproteinemic subjects.
Postprandial triglyceride measurements
Measuring plasma triglycerides after a fat load provides an indirect assessment of chylomicron remnant clearance. Dietary interventions can alter postprandial triglyceride curves, reflecting changes in clearance efficiency. This approach is widely used in clinical studies of dyslipidemia.
CRISPR knockout and knock-in models
CRISPR knockout of candidate hepatic receptors or apolipoproteins allows direct testing of their role in chylomicron remnant clearance. Knock-in of disease-associated variants can reproduce delayed clearance phenotypes. These models are essential for causal inference in lipid metabolism research.
In vivo kinetic studies in animal models
Animal models, particularly mice, are used to study chylomicron remnant clearance kinetics. Radiolabeled or fluorescently labeled remnants can be injected to measure hepatic uptake. Such studies complement human kinetic data.
How CRISPR Can Be Used to Study GO:0034382 chylomicron remnant clearance
Knockout
CRISPR knockout of genes such as APOE, LDLR, or LRP1 in hepatocyte models can directly test their requirement for chylomicron remnant clearance. Loss of function is expected to delay or abolish remnant uptake, providing causal evidence. These models are foundational for mechanistic studies of GO:0034382.
Point Mutation
Point mutations in APOE or other ligand genes can be introduced to mimic human variants associated with delayed clearance. Such models allow precise structure-function analysis of receptor-ligand interactions. They are particularly useful when complete knockout is lethal or confounded.
Knock-in
Knock-in of human disease-associated alleles into mouse models can reproduce impaired chylomicron remnant clearance. This approach helps validate genetic findings from human studies. It also enables testing of allele-specific effects on clearance kinetics.
Overexpression
Overexpression of candidate genes, such as those encoding receptors or apolipoproteins, can test whether increased expression accelerates remnant clearance. This is useful for identifying rate-limiting components. Overexpression models complement knockout studies by providing gain-of-function evidence.
How EDITGENE Supports chylomicron remnant clearance Research
Researchers studying chylomicron remnant clearance-related genes often need to determine whether a candidate gene is causally involved in remnant uptake and degradation. EDITGENE provides CRISPR-based cell model services to enable such functional studies with high specificity and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for chylomicron remnant clearance research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| APOE Knockout HEK293 Cell Line | EDJ-KQ172 | Human | 348 | Details Get a Quote |
| LIPC Knockout HEK293 Cell Line | EDJ-KQ2798 | Human | 3990 | Details Get a Quote |
| APOC3 Knockout HEK293 Cell Line | EDJ-KQ3340 | Human | 345 | Details Get a Quote |
| APOE Knockout A-549 Cell Line | EDJ-KQ41271 | Human | 348 | Details Get a Quote |
| APOE Knockout HCT 116 Cell Line | EDJ-KQ41272 | Human | 348 | Details Get a Quote |
| APOE Knockout HeLa Cell Line | EDJ-KQ41273 | Human | 348 | Details Get a Quote |
| APOE Knockout LLC-MK2 Cell Line | EDJ-KZ546 | Rhesus Monkey | 714623 | Details Get a Quote |
| APOC1 Knockout HEK293 Cell Line | EDJ-KQ50124 | Human | 341 | Details Get a Quote |
| APOC2 Knockout HEK293 Cell Line | EDJ-KQ50125 | Human | 344 | Details Get a Quote |
| APOC1 Knockout HeLa Cell Line | EDJ-KQ52634 | Human | 341 | Details Get a Quote |
| APOC2 Knockout HeLa Cell Line | EDJ-KQ52636 | Human | 344 | Details Get a Quote |
| APOC3 Knockout HeLa Cell Line | EDJ-KQ52637 | Human | 345 | Details Get a Quote |
| LIPC Knockout HeLa Cell Line | EDJ-KQ53796 | Human | 3990 | Details Get a Quote |
| APOC1 Knockout A-549 Cell Line | EDJ-KQ61109 | Human | 341 | Details Get a Quote |
| APOC2 Knockout A-549 Cell Line | EDJ-KQ61111 | Human | 344 | Details Get a Quote |
Displaying Records 1 To 15 Of 22 Records
Frequently Asked Questions About chylomicron remnant clearance
What is chylomicron remnant clearance?
Chylomicron remnant clearance (GO:0034382) is the process in which chylomicron remnants are removed from the blood via receptor-mediated endocytosis into liver cells and degraded.
What genes are involved in chylomicron remnant clearance?
Key genes include APOE, LDLR, LRP1, APOB, APOC3, LPL, and APOA5, among others.
How is chylomicron remnant clearance measured?
It can be measured using vitamin A loading, retinyl ester kinetics, and postprandial triglyceride curves.
What diseases are associated with impaired chylomicron remnant clearance?
Familial combined hyperlipidemia, heterozygous familial hypercholesterolaemia, and hypertriglyceridemia are associated with delayed clearance.
Does diet affect chylomicron remnant clearance?
Yes, dietary interventions, including fat quantity and type, can affect chylomicron and chylomicron remnant clearance.
What is the role of apolipoprotein E in chylomicron remnant clearance?
Apolipoprotein E on remnant surfaces mediates recognition by hepatic receptors, facilitating receptor-mediated endocytosis.
Can CRISPR be used to study chylomicron remnant clearance?
Yes, CRISPR knockout, knock-in, and overexpression models are used to test the role of specific genes in this process.
What is the difference between chylomicron and chylomicron remnant clearance?
Chylomicron clearance refers to the removal of intact chylomicrons, while remnant clearance specifically refers to the uptake of partially lipolyzed remnants by the liver.
Is chylomicron remnant clearance relevant to cardiovascular disease?
Yes, delayed clearance leads to prolonged circulation of atherogenic remnants, which is associated with increased cardiovascular risk.
What cell types are involved in chylomicron remnant clearance?
Hepatocytes are the primary cells responsible for receptor-mediated endocytosis and degradation of chylomicron remnants.
Conclusion
Chylomicron remnant clearance (GO:0034382) is a critical biological process that determines the fate of dietary fats and fat-soluble vitamins after a meal. Its impairment is linked to common dyslipidemias and increased cardiovascular risk. Understanding the genes and mechanisms controlling this process is essential for developing targeted therapies. CRISPR-based models offer powerful tools to dissect the molecular players involved in chylomicron remnant clearance.
References
- 1. Willnow TE. 1997. Mechanisms of hepatic chylomicron remnant clearance.. Diabet Med 14 Suppl 3:S75-80 PMID: 9272618
- 2. Williams CM. 1998. Dietary interventions affecting chylomicron and chylomicron remnant clearance.. Atherosclerosis 141 Suppl 1:S87-92 PMID: 9888649
- 3. Rassin T et al.. 1992. Vitamin A loading--an indicator of post-prandial lipoprotein clearance in healthy and hypertriglyceridemic subjects.. Isr J Med Sci 28(10):706-10 PMID: 1399499
- 4. Hassing HC et al.. 2012. Pathophysiology of hypertriglyceridemia.. Biochim Biophys Acta 1821(5):826-32 PMID: 22179026
- 5. Cabezas MC et al.. 1993. Impaired chylomicron remnant clearance in familial combined hyperlipidemia.. Arterioscler Thromb 13(6):804-14 PMID: 8499400
- 6. Cabezas MC et al.. 1998. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia.. J Intern Med 244(4):299-307 PMID: 9797493
- 7. Cortner JA et al.. 1987. Kinetics of chylomicron remnant clearance in normal and in hyperlipoproteinemic subjects.. J Lipid Res 28(2):195-206 PMID: 3572247
- 8. Redgrave TG. 2004. Chylomicron metabolism.. Biochem Soc Trans 32(Pt 1):79-82 PMID: 14748717
